Healthcare Industry News: CMS Inc
News Release - July 20, 2007
CMS, Inc. Applies for 510(k) for Monaco(TM), The Next Generation in IMRT Planning
ST. LOUIS--(HSMN NewsFeed)--CMS, Inc., the worldwide market leader in radiation treatment planning and workflow management solutions, has completed internal and external validation testing for its new Monaco IMRT planning system. The company has proceeded with applying to the Food and Drug Administration for 510(k) clearance to distribute Monaco in the U.S. market. The software has already obtained its CE mark and the first customer installations in Europe are being scheduled for this summer.Monaco represents a fundamentally new approach to IMRT planning. These concepts represent a unique and sophisticated set of tools to make the radiotherapy planning process easier, more straightforward, and clinically reliable. The result is that clinicians are empowered with better tools to provide a higher standard of patient care.
"We are enthusiastic about the pending review and approval to distribute Monaco in the U.S. market," said Andrew C. Cowen, President and Chief Executive Officer of CMS. "This will be the first Monte Carlo-based IMRT planning solution commercially available in the world, and one that further incorporates a number of new and exciting concepts for IMRT planning. Monaco shows great promise to enhance efficiency and accuracy and the quality of care our clinical partners can provide to patients."
IMRT delivers significant improvements for radiation treatment and cancer patients, but the technology poses clinical challenges as well. A major challenge has been managing the time and resource intensive processes associated with IMRT planning. With Monaco, CMS offers new approaches designed to improve the following:
- Repetitive trial-and-error methods for determining the optimal plan
- Multiple variables to manage the planning process including patient data, contours, and the optimization itself
- A generally non-intuitive IMRT planning process
- A lack of control over the "black box" optimization process
Monaco was developed with the University of Tubingen in Germany. Markus Alber, Ph.D. and colleagues developed the Hyperion project, which is the engine behind the new Monaco system. CMS commercialized these innovative concepts and approaches from the Hyperion project to create the foundation for Monaco. The result is an advanced, clinically sophisticated IMRT planning system backed by the core research and capabilities of one of the world's leading research institutions.
CMS is a worldwide leader in the development and support of radiation treatment planning and workflow management solutions. With treatment planning systems installed in more than 1,500 sites worldwide, CMS is a global resource to the radiation oncology community. A privately held corporation, CMS employs 285 professionals in its headquarters located in St. Louis, MO and regional offices in Tampa, Florida; Freiburg, Germany; Tokyo, Japan; Sydney, Australia; and Shanghai, China.
Forward-Looking Statements
Statements contained in this release, which are not historical facts, may be considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and the current economic environment.
We caution the reader that such forward-looking statements are not guarantees of future performance. Unknown risk, uncertainties as well as other uncontrollable or unknown factors could cause actual results to materially differ from the results, performance or expectations expressed or implied by such forward-looking statements
Source: CMS, Inc
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!